PURPOSE OF STUDY: Heart failure is a chronic disease that can progress and lead to hospitalisation(s). Methamphetamine is a commonly used recreational drug and has been reports of associations with cardiomyopathy. The objective of this study was to describe the chronic disease and epidemiology on methamphetamine cardiomyopathy and to objectify the reversibility. METHODS USED: Data Collection –In this retrospective study, 116 patients were identified with inclusion criteria of having methamphetamine cardiomyopathy, left ventricular ejection fraction ≤40% and age ≥18.Data was collected through uniform query of community hospital database on patient demographics, medical history, social history, number of heart failure hospitalizations, and cardiac imaging. SUMMARY OF RESULTS: Of the 116 identified patients, 53 patients (46%) had improvement of left ventricular ejection fraction with cessation of methamphetamine use and adherence to guideline-directed therapy. Of the 53 patients 83% (47/53) were males. Twenty-three percent (12/53) had BMI less than 25% and 23% (12/53) were super obese (BMI >40). Diabetes mellitus was a co-morbidity for 32% (17/53) of the patients and of these, 88% (15/17) had improvement of left ventricular ejection fraction ≥40% after drug cessation and medical therapy. Tobacco dependence existed in 81% (43/53) of the patients and alcohol use in 47% (25/53). Forty-five percent (24/53) had at least 2 heart failure exacerbation hospitalizations. Of the patients identified with 3 or greater heart failure exacerbation hospitalizations, 75% (39/53) had hypertension. After cessation of methamphetamines, 69% (37/53) of patients had complete reversibility of left ventricular ejection fraction (left ventricular ejection fraction ≥40%). CONCLUSIONS: Hypertension was the most common co-morbidity. Despite having hypertension, diabetes mellitus, and/or dyslipidemia, patients were able to have improvement in heart failure. Methamphetamine cardiomyopathy related hospitalisation and morbidity can decrease with medical therapy and cessation of drug use. Further studies are warranted to improve understanding of methamphetamine cardiomyopathy.